Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.

By S. Michels, P. Rosenfeld, C. Puliafito, E. Marcus, A. Venkatraman. Ophthalmology (Rochester, Minn.), 2005

712 citations recorded by the source corpus.

Subfields: Epidemiology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/5a8041e0372c7a9e98a4224585ebe1075d6d6442

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. T. van Leeuwen
2. M. D. de Smet
3. D. Faber
4. F. Verbraak
5. M. V. van Velthoven
6. D. Hood

Citations in the corpus

• Recent developments in optical coherence tomography for imaging the retina. (2007, background): “, 2006a) or in monitoring the effect of recently introduced antiangiogenic drugs (Rosenfeld et al., 2005; Michels et al., 2005; Avery et al., 2006).”
• DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (2006, neutral): “terminal domain (111-165) of vascular endothelial growth”